Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Are the Key Projections for the CAGR of the Eosinophilic Asthma Market Size From 2025 to 2034?

The market size for eosinophilic asthma has seen substantial growth in recent times. It is set to rise from $2.69 billion in 2024 to $3.17 billion in 2025, with a compound annual growth rate (CAGR) of 17.7%. The expansion during the historic period can be linked to the increase in pollution, a decrease in population immunity, a surge in the occurrence of eosinophilic asthma, a rise in allergens and respiratory conditions, an increase in healthcare spending, and an elevation in research and development activities.

In the upcoming years, the eosinophilic asthma market is set to experience accelerated growth. It is predicted to expand to a worth of $6.01 billion by 2029, displaying a compound annual growth rate (CAGR) of 17.4%. This growth over the projection period can be linked to several factors, including the rising prevalence of respiratory illnesses, greater awareness and diagnosis rates, broadening applications for monoclonal antibodies, increased healthcare infrastructure investment, and an upsurge in bespoke medical approaches. Noteworthy trends for this forecasted period encompass the establishment of targeted biologics, advancement in diagnostic tools, tailored treatment methods, bolstered drug delivery systems, merging with digital health technologies, and augmented clinical trials for new therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Eosinophilic Asthma Market?

The growth of the eosinophilic asthma market is propelled by increasing smoking habits. The term ‘smoking habits’ encompasses regular usage and patterns of tobacco consumption, including the frequency, context, and duration of smoking, which are generally influenced by psychological, social, and environmental factors. The increase in smoking habits can be attributed to factors such as elevated stress levels, targeted advertising campaigns by tobacco manufacturers, lack of understanding of health-related risks, and the social acceptance of smoking in specific cultures. Eosinophilic asthma treatment reduces airway inflammation and improves lung function, which can promote smoking cessation by easing the respiratory complications that often compel patients to keep smoking. For example, in December 2023, the National Health Service, a UK-based government agency, reported an estimated 408,700 hospital admissions due to smoking in 2022–23, which is an increase of 4.8% from 389,800 in 2021–22. Hence, the escalating smoking rates contribute towards the growth of the eosinophilic asthma market.

Which Primary Segments of the Eosinophilic Asthma Market Are Driving Growth and Industry Transformations?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

Which Regions Are Key Players in the Growth of the What Are the Primary Drivers Supporting the Market Growth of the Eosinophilic Asthma Market? Market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Eosinophilic Asthma Market?

Key players in the eosinophilic asthma market are focusing on the creation of novel drugs to specifically target immune pathways, reduce inflammation, and better the results of patient treatment through individualized treatments. One such method involves the use of monoclonal antibodies, which are essentially laboratory-created molecules that replicate the immune system’s ability to combat harmful viruses and bacteria. The creation of these antibodies involves merging a specific antibody-producing cell with a cancer cell, thus allowing for the mass production of identical antibodies. For example, in August 2024, AstraZeneca plc, a biopharmaceutical firm based in the UK, made public the approval of Fasenra by the China’s National Medical Products Association for the treatment of severe eosinophilic asthma. The condition, severe eosinophilic asthma, is distinguished by high eosinophil counts which can trigger inflammation and an exacerbation of asthma symptoms. Fasenra, a monoclonal antibody, aims to target and eliminate eosinophils using a distinctive mechanism. By latching onto the IL-5 receptor on eosinophils, Fasenra can boost the immune system’s capability and lower eosinophil levels in blood and tissue. The treatment regimen starts with a loading phase before transitioning to maintenance doses. Generally, patients receive injections every four weeks for the first three doses, with the frequency reducing to every eight weeks subsequently.

View the full report here:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

What Parameters Are Used to Define the Eosinophilic Asthma Market?

Eosinophilic asthma is a form of asthma where high eosinophil counts, a specific white blood cell type, cause airway inflammation. This condition results in severe symptoms such as breathing issues and recurring flare-ups, with limited effectiveness from standard treatments such as inhaled steroids.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model